South Korea · Delayed Price · Currency is KRW HEM Pharma Statistics
Total Valuation
HEM Pharma has a market cap or net worth of KRW 244.39 billion. The enterprise value is 256.09 billion.
| Market Cap | 244.39B |
| Enterprise Value | 256.09B |
Important Dates
The next estimated earnings date is Friday, November 27, 2026.
| Earnings Date | Nov 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HEM Pharma has 7.21 million shares outstanding. The number of shares has increased by 6.02% in one year.
| Current Share Class | 7.21M |
| Shares Outstanding | 7.21M |
| Shares Change (YoY) | +6.02% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 25.83% |
| Owned by Institutions (%) | 4.33% |
| Float | 4.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.14 |
| PB Ratio | 14.90 |
| P/TBV Ratio | 19.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.66, with a Debt / Equity ratio of 1.18.
| Current Ratio | 0.66 |
| Quick Ratio | 0.33 |
| Debt / Equity | 1.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.04 |
| Interest Coverage | -12.70 |
Financial Efficiency
Return on equity (ROE) is -108.52% and return on invested capital (ROIC) is -31.04%.
| Return on Equity (ROE) | -108.52% |
| Return on Assets (ROA) | -22.85% |
| Return on Invested Capital (ROIC) | -31.04% |
| Return on Capital Employed (ROCE) | -78.84% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.35 |
| Inventory Turnover | 4.29 |
Taxes
| Income Tax | -3.18B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +38.37% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +38.37% |
| 50-Day Moving Average | 39,388.00 |
| 200-Day Moving Average | 55,027.00 |
| Relative Strength Index (RSI) | 33.80 |
| Average Volume (20 Days) | 10,142 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HEM Pharma had revenue of KRW 16.14 billion and -20.87 billion in losses. Loss per share was -2,925.70.
| Revenue | 16.14B |
| Gross Profit | 2.05B |
| Operating Income | -17.02B |
| Pretax Income | -23.92B |
| Net Income | -20.87B |
| EBITDA | -14.27B |
| EBIT | -17.02B |
| Loss Per Share | -2,925.70 |
Balance Sheet
The company has 9.56 billion in cash and 19.32 billion in debt, with a net cash position of -9.76 billion or -1,353.97 per share.
| Cash & Cash Equivalents | 9.56B |
| Total Debt | 19.32B |
| Net Cash | -9.76B |
| Net Cash Per Share | -1,353.97 |
| Equity (Book Value) | 16.40B |
| Book Value Per Share | 2,010.06 |
| Working Capital | -11.88B |
Cash Flow
In the last 12 months, operating cash flow was -7.42 billion and capital expenditures -11.23 billion, giving a free cash flow of -18.66 billion.
| Operating Cash Flow | -7.42B |
| Capital Expenditures | -11.23B |
| Depreciation & Amortization | 2.75B |
| Net Borrowing | 16.61B |
| Free Cash Flow | -18.66B |
| FCF Per Share | -2,587.78 |
Margins
Gross margin is 12.69%, with operating and profit margins of -105.44% and -129.31%.
| Gross Margin | 12.69% |
| Operating Margin | -105.44% |
| Pretax Margin | -148.21% |
| Profit Margin | -129.31% |
| EBITDA Margin | -88.42% |
| EBIT Margin | -105.44% |
| FCF Margin | n/a |
Dividends & Yields
HEM Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.02% |
| Shareholder Yield | -6.02% |
| Earnings Yield | -8.54% |
| FCF Yield | -7.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HEM Pharma has an Altman Z-Score of 1.97 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.97 |
| Piotroski F-Score | 2 |